BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

BACKGROUND: Activating mutation of KRAS and BRAF are focused on as potential prognostic and predictive biomarkers in patients with colorectal cancer (CRC) treated with anti-EGFR therapies. This study investigated the clinicopathological features and prognostic impact of KRAS/BRAF mutation in advance...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Yokota, T, Ura, T, Shibata, N, Takahari, D, Shitara, K, Nomura, M, Kondo, C, Mizota, A, Utsunomiya, S, Muro, K, Yatabe, Y
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2011
Témata:
Molecular Diagnostics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3048210/
https://ncbi.nlm.nih.gov/pubmed/21285991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.19
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky